Literature DB >> 31036735

Detection of a new melanoma in a patient treated with fingolimod.

Yves Michiels1, Olivier Bugnon1,2, Jean-François Michiels3, Sophie Mazellier3.   

Abstract

In addition to the TRANSFORMS, FREEDOMS, INFORMS studies, very few publications have identified new cases of skin cancer in patients treated with fingolimod. Here, we present the case of a 52-year-old Caucasian patient with relapsing remitting multiple sclerosis for 19 years, with a phototype II with blue eyes, light brown hair, no personal or family history of melanoma and a low number of naevi (<10). She did not experience intense sun exposure in childhood as well as severe sunburn and did not practise sessions in ultraviolet cabins. This case is distinguished from other published cases, usually superficial spreading malignant melanoma by its unclassifiable histological character. The occurrence of skin cancers in patients with multiple sclerosis remains exceptional, but new cases have recently emerged requiring the strengthening of dermatological follow-up of such patients. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; malignant disease and immunosuppression; multiple sclerosis; neurology (drugs and medicines)

Mesh:

Substances:

Year:  2019        PMID: 31036735      PMCID: PMC6506067          DOI: 10.1136/bcr-2018-227951

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.

Authors:  G Haebich; A Mughal; N Tofazzal
Journal:  Clin Exp Dermatol       Date:  2015-11-18       Impact factor: 3.470

2.  Melanoma following treatment with alemtuzumab for multiple sclerosis.

Authors:  A A Pace; J P Zajicek
Journal:  Eur J Neurol       Date:  2009-04       Impact factor: 6.089

3.  Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.

Authors:  Katrin Baumann Conzett; Isabel Kolm; Ilijas Jelcic; Jivko Kamarachev; Reinhard Dummer; Ralph Braun; Lars E French; Michael Linnebank; Günther F L Hofbauer
Journal:  Arch Dermatol       Date:  2011-08

4.  Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.

Authors:  Alberto Calvi; Milena De Riz; Elisabetta Lecchi; Anna Pietroboni; Laura Ghezzi; Marta Scarioni; Tiziana Carandini; Alessandro Pellegrinelli; Andrea Maurichi; Daniela Galimberti; Elio Scarpini
Journal:  J Neurol Sci       Date:  2017-09-05       Impact factor: 3.181

5.  Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Authors:  Joep Killestein; Cyra E Leurs; Erwin L J Hoogervorst; Jeroen van Eijk; Jop P Mostert; Alfons J M van den Eertwegh; Bernard M J Uitdehaag
Journal:  Neurology       Date:  2017-08-02       Impact factor: 9.910

Review 6.  Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Authors:  Christine Lebrun; Fanny Rocher
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

Review 7.  Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Rachel A Sabol; Virginia Noxon; Oliver Sartor; Joseph R Berger; Zaina Qureshi; Dennis W Raisch; LeAnn B Norris; Paul R Yarnold; Peter Georgantopoulos; William J Hrushesky; Laura Bobolts; Paul Ray; Akida Lebby; Robert C Kane; Charles L Bennett
Journal:  Cancer Med       Date:  2017-06-20       Impact factor: 4.452

  7 in total
  1 in total

1.  Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Authors:  Omar Hasan Ali; Fiamma Berner; Christoph Jakob Ackermann; Sandra Stephanie Ring; Alexandre Moulin; Joachim Müller; Eva Markert; Oltin Tiberiu Pop; Stefanie Müller; Stefan Diem; Thomas Hundsberger; Lukas Flatz
Journal:  Cancer Immunol Immunother       Date:  2020-08-17       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.